Denali Therapeutics (NASDAQ:DNLI) Earns “Outperform” Rating from William Blair

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “outperform” rating restated by equities research analysts at William Blair in a research report issued on Wednesday,RTT News reports.

A number of other equities research analysts have also weighed in on the stock. Robert W. Baird started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an “outperform” rating and a $31.00 target price on the stock. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. HC Wainwright decreased their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Jefferies Financial Group lifted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $21.67 on Wednesday. The stock has a market cap of $3.12 billion, a P/E ratio of -7.85 and a beta of 1.39. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The stock has a 50 day simple moving average of $23.32 and a two-hundred day simple moving average of $24.74.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the firm earned ($0.72) earnings per share. Sell-side analysts predict that Denali Therapeutics will post -2.73 earnings per share for the current year.

Insider Buying and Selling

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. The trade was a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,518 shares of company stock worth $1,469,382 in the last quarter. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. American Century Companies Inc. boosted its position in shares of Denali Therapeutics by 13.7% during the second quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after buying an additional 63,058 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock valued at $32,913,000 after acquiring an additional 84,522 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $249,000. Hsbc Holdings PLC raised its holdings in shares of Denali Therapeutics by 83.1% during the second quarter. Hsbc Holdings PLC now owns 29,642 shares of the company’s stock valued at $668,000 after purchasing an additional 13,454 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Denali Therapeutics by 87.8% during the second quarter. Sei Investments Co. now owns 22,670 shares of the company’s stock valued at $526,000 after purchasing an additional 10,598 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.